CDK8抑制增加了E2F1的转录活性,并促进了三阴性乳腺癌细胞系MDA-MB-46868中STAT3依赖的Mcl-1抑制
Sandra Do1, Shengxi Li1, Rui Xiong1
1Department of Pharmaceutical Sciences, Thomas J. Long School of Pharmacy, University of the Pacific, Stockton, CA 95211, USA.
International journal of molecular sciences
|January 28, 2026
概括
用抑制剂向循环素依赖性激酶8 (CDK8) 显示出对三阴性乳腺癌的前景. 抑制CDK8会影响E2F1和STAT3等关键蛋白质,调节细胞亡并提供潜在的治疗策略.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 生物化学 生物化学
背景情况:
- 循环素依赖激酶8 (CDK8) 被认为是一种瘤基因产物.
- 向CDK8是癌症治疗的一个发展战略.
- 三阴性乳腺癌 (TNBC) 提出了独特的治疗挑战.
研究的目的:
- 为了研究CDK8抑制剂对MDA-MB-468三阴性乳腺癌细胞系的影响.
- 阐明TNBC细胞中CDK8抑制背后的分子机制.
主要方法:
- 用CDK8抑制剂治疗MDA-MB-468细胞.
- 评估CDK8基质的酸化,包括E2促进体结合因子1 (E2F1) 和信号转换器和转录3激活器 (STAT3).
- 对 luciferase 记者基因表达的分析,p73 和骨髓细胞白血病序列 1 (Mcl-1) 蛋白质水平,以及 STAT3 淘汰效应.
主要成果:
- 抑制CDK8降低了E2F1和STAT3的酸化.
- 在E2F1响应细胞中观察到 luciferase 表达的增加.
- CDK8抑制导致p73增加和Mcl-1表达减少.
- STAT3 敲击抵消了 CDK8 抑制对 Mcl-1 的影响.
结论:
- 用CDK8抑制剂治疗可以调节TNBC细胞中与亡相关的蛋白质p73和Mcl-1.
- E2F1和STAT3信号通路合作参与CDK8抑制剂活性.
- 这些发现凸显了CDK8抑制剂对抗三阴性乳腺癌的治疗潜力.
关键词:
CDK8 CDK8 CDK8 CDK8 CDK8 CDK8 CDK8 CDK8 CDK8 CDK8 CDK8 CDK8 CDK8 CDK8 CDK8 CDK8 CDK8 CDK8 CDK8 CDK8 CDK8 CDK8 CDK8 CDK8 CDK8 CDK8 CDK8 CDK8 CDK8 CDK8 CDK8 CDK8 CDK8 CDK8 CDK8 CDK8 CDK8 CDK8 CDK8 CDK9 CDK8 CDK9 CDK8 CDK9 CDK9 CDK9 CDK9 CDK9 CDK9 CDK9 CDK9 CDK9 CDK9 CDK9 CDK9 CDK9 CDK9 CDK9 CDK9 CDK9 CDK9 CDK9 CDK9 CDK9 CDK9 CDK9E2F1 E2F1 E2F1 E2F1 E2F1 E2F1 E2F1 E2F1 E2F1在Mcl-1中.在STAT3中,我们可以使用STAT3.酶抑制剂是一种酶抑制剂.三重阴性乳腺癌是什么
相关概念视频
01:58Prokaryotic Transcriptional Activators and Repressors
25.4K
The organization of prokaryotic genes in their genome is notably different from that of eukaryotes. Prokaryotic genes are organized, such that the genes for proteins involved in the same biochemical process or function are located together in groups. This group of genes, along with their regulatory elements, are collectively known as an operon. The functional genes in an operon are transcribed together to give a single strand of mRNA known as polycistronic mRNA.
Transcription of prokaryotic...
Transcription of prokaryotic...
25.4K
02:42Eukaryotic Transcription Activators
12.8K
Transcription activators are proteins that promote the transcription of genes from DNA to RNA. In most cases, these proteins contain two separate domains ‒ a domain that binds to DNA and a domain for activating transcription; however, in some cases, a single domain is responsible for both binding and activation of transcription, as seen in the glucocorticoid receptor and MyoD.
The binding domains are capable of recognizing and interacting with regulatory sequences on the DNA. These...
The binding domains are capable of recognizing and interacting with regulatory sequences on the DNA. These...
12.8K
02:40The Eukaryotic Promoter Region
18.8K
The eukaryotic promoter region is a segment of DNA located upstream of a gene. It contains an RNA polymerase binding site, a transcription start site, and several cis-regulatory sequences. The proximal promoter region is located in the vicinity of the gene and has cis-regulatory sequences and the core promoter. The core promoter is the binding site for RNA polymerase and is usually located between -35 and +35 nucleotides from the transcription start site. The distal promoter regions are...
18.8K
01:23Negative Regulator Molecules
38.5K
Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
38.5K
02:23Master Transcription Regulators
7.8K
Master transcription regulators are regulatory proteins that are predominantly responsible for regulating the expression of multiple genes. Often these genes work in concert to drive a complex process. Activation of a master transcription regulator can lead to a cascade of transcriptional activation necessary for that outcome. These regulators can directly bind to the regulatory sequences of the various genes involved, or they can indirectly regulate transcription by binding to regulatory...
7.8K
02:34Inhibition of Cdk Activity
6.0K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.0K